Search Results

Authorities have launched inspections and enforcement actions to curb misuse of GLP-1 based weight loss drugs.

Even brief interruption tied to change in risk of heart attack, stroke and death.

Analysis of nearly 8,000 adults found 45% keep the weight off after one year.

FDA inspection finds safety reporting gaps at Novo Nordisk involving serious adverse events linked to widely used GLP-1 diabetes and obesity drugs

Drugs also related to lower use of drugs to stop, prevent attacks.

WHO’s first guideline on GLP-1 therapies warns that weight-loss drugs alone won’t solve obesity, urging comprehensive care, healthy habits, and safer access policies